# Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

> **NCT05702424** · PHASE1 · COMPLETED · sponsor: **IGM Biosciences, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** IGM-7354

## Key facts

- **NCT ID:** NCT05702424
- **Lead sponsor:** IGM Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-10
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05702424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05702424, "Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05702424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*